"TCG Lifesciences congratulates Curadev for its recent research collaboration and licensing agreement to develop cancer immunotherapeutic candidate"
Kolkata, India - June 8, 2015 - TCG Lifesciences Limited (formerly "Chembiotek Research International"), a leading contract research services company in the area of early drug discovery and development congratulates Curadev Pharma Private Limited for its research collaboration and exclusive license agreement for the development and commercialization of IDO1 and TDO inhibitors.
TCG Lifesciences provided chemistry synthesis of molecules and preliminary scale up of the lead molecule for Curadev.
"Speed is the key to winning,” said Dr.Subho Roy, Associate VP - TCG Lifesciences, “TCG scientists developed innovative synthetic routes with tight cycle times to deliver the lead molecules which were quickly optimized. Subsequently, TCG developed a cost effective route for rapid scale up of the desired API.”
"We applaud Curadev for this achievement," said Swapan Bhattacharya, Managing Director TCG Lifesciences. "They identified the target long before immuno-oncology became a “red hot” area for cancer therapy and focused tenaciously on this program despite many challenges. Curadev has put India on the map for development of innovative and novel drug candidates at the frontiers of science."
About TCG Lifesciences
TCG Lifesciences Limited (formerly "Chembiotek Research International") is a leading contract research services company in the area of early drug discovery and development.It started its operations in the year 2001 in India; currently it has its presence in United States, Europe and Japan. It is part of ‘The Chatterjee Group’, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its units Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with many global pharmaceutical companies which span from specific solutions and sourcing services to integrated projects across multiple domains in the early drug discovery and development space. Learn more at http://www.tcgls.com
For further information:Rakesh Pandya, VP Finance, firstname.lastname@example.org